keppra concentrate for solution for infusion 100 mgml
glaxosmithkline pte ltd - levetiracetam - infusion, solution concentrate - 500 mg per vial - levetiracetam 500 mg per vial
keppra oral solution 100 mgml
glaxosmithkline pte ltd - levetiracetam - solution - 100 mg/ml - levetiracetam 100 mg/ml
keppra tablet 1000 mg
glaxosmithkline pte ltd - levetiracetam - tablet, film coated - 1000 mg - levetiracetam 1000 mg
keppra tablet 250 mg
glaxosmithkline pte ltd - levetiracetam - tablet, film coated - 250 mg - levetiracetam 250 mg
keppra tablet 500 mg
glaxosmithkline pte ltd - levetiracetam - tablet, film coated - 500 mg - levetiracetam 500 mg
keppra 250 mg
cts ltd - levetiracetam - film coated tablets - levetiracetam 250 mg - levetiracetam - levetiracetam - - keppra is indicated as adjunctive therapy in the treatment of partial onset seizures with or without secondary generalisation in adults and children from 4 years of age with epilepsy. - keppra is indicated as adjunctive therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy. - keppra is indicated as monotherapy in the treatment of partial onset seizures with or without secondary generalization in patient from 16 years of age with newly diagnosed epilepsy. - keppra is indicated as adjunctive therapy in the treatment of primary gneralized tonic-clonic seizures in adults and adolescents from 12 years of age with idiopathic generalised epilepsy.
keppra 500 mg
cts ltd - levetiracetam - film coated tablets - levetiracetam 500 mg - levetiracetam - levetiracetam - - keppra is indicated as adjunctive therapy in the treatment of partial onset seizures with or without secondary generalisation in adults and children from 4 years of age with epilepsy. - keppra is indicated as adjunctive therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy. - keppra is indicated as monotherapy in the treatment of partial onset seizures with or without secondary generalization in patient from 16 years of age with newly diagnosed epilepsy. - keppra is indicated as adjunctive therapy in the treatment of primary gneralized tonic-clonic seizures in adults and adolescents from 12 years of age with idiopathic generalised epilepsy.
keppra 1000 mg
cts ltd - levetiracetam - film coated tablets - levetiracetam 1000 mg - levetiracetam - levetiracetam - - keppra is indicated as adjunctive therapy in the treatment of partial onset seizures with or without secondary generalisation in adults and children from 4 years of age with epilepsy. - keppra is indicated as adjunctive therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy. - keppra is indicated as monotherapy in the treatment of partial onset seizures with or without secondary generalization in patient from 16 years of age with newly diagnosed epilepsy. - keppra is indicated as adjunctive therapy in the treatment of primary gneralized tonic-clonic seizures in adults and adolescents from 12 years of age with idiopathic generalised epilepsy.
keppra oral solution
cts ltd - levetiracetam - solution - levetiracetam 100 mg/ml - levetiracetam - levetiracetam - keppra is indicated as monotherapy in the treatment of partial onset seizures with or without secondary generalisation in patients from 16 years of age with newly diagnosed epilepsy. keppra is indicated as adjunctive therapy - in the treatment of partial onset seizures with or without secondary generalisation in adults and children from 4 years of age with epilepsy. - in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy. - in the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with idiopathic generalised epilepsy.
levetiracetam aurobindo 250 milligram film coated tablet
milpharm limited - levetiracetam - film coated tablet - 250 milligram - other antiepileptics